ozenoxacin

General

Pronunciation:
oz-en-ox-a-sin


Trade Name(s)

  • Xepi

Ther. Class.
anti-infectives

Pharm. Class.
fluoroquinolones

Indications

Impetigo.

Action

Inhibits bacterial DNA synthesis by inhibiting DNA gyrase A and topoisomerase IV.

Therapeutic Effect(s):

Death of susceptible bacteria.

Spectrum: Active against gram-positive pathogens, including:
  • Staphylococcus aureus
  • Streptococcus pyogenes.

Pharmacokinetics

Absorption: Minimal systemic absorption.

Distribution: Not applicable because of minimal systemic absorption.

Metabolism and Excretion: Not applicable because of minimal systemic absorption.

Half-life: Not applicable because of minimal systemic absorption.

TIME/ACTION PROFILE

ROUTEONSETPEAKDURATION
Topicaln/an/an/a

Contraindication/Precautions

Contraindicated in:

  • None.

Use Cautiously in:

  • OB:  Lactation: Safety not established; fetal exposure not expected due to minimal systemic absorption;
  • Pedi:  Children <2 mo (safety and effectiveness not established).

Adverse Reactions/Side Effects

Derm: rosacea, seborrheic dermatitis

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

None known.

Route/Dosage

Topical  (Adults and Children)  ≥2 mo) Apply to affected area twice daily for 5 days.

Availability

Cream: 1%

Assessment

  • Assess skin lesions prior to and periodically during and following therapy.

Potential Diagnoses

Implementation

  • Topical  Apply a thin layer to affected area twice daily for five days. Wash hands after application. May cover treated area with sterile bandage or gauze dressing. Not for oral, ophthalmic, intranasal, or intravaginal use.

Patient/Family Teaching

  • Instruct patient or parent in correct technique for application and to apply only in treatment area. Advise patient or parent to wash hands following application. Instruct patient or parent to use ozenoxacin for entire prescribed time, even if symptoms improved.
  • Advise patient or parent to notify health care professional is no improvement is seen after 3 days of therapy.

Evaluation/Desired Outcomes

Resolutions of skin lesions.

ozenoxacin is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. .